Suzhou, China, February 10, 2023- Suzhou Puhe Biopharma announced today that its application for Phase III clinical trial for a small molecule innovative drug (PH001) in the field of lung cancer has been accepted and approved by the National Medical Products Administration for use in advanced NSCLC patients with EGFR Ex20ins who have not undergone systematic treatment.